Robin Uchiyama1, Benoit Chassaing2, Benyue Zhang2, Andrew T Gewirtz1. 1. Center for Inflammation, Immunity, and Infection, Georgia State University Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, Georgia. 2. Center for Inflammation, Immunity, and Infection, Georgia State University.
Abstract
BACKGROUND: Rotavirus causes 500 000 deaths and millions of physician visits and hospitalizations per year, with worse outcomes and reduced vaccine efficacy in developing countries. We hypothesized that the gut microbiota might modulate rotavirus infection and/or antibody response and thus potentially play a role in such regional differences. METHODS: The microbiota was ablated via germ-free or antibiotic approaches. Enhanced exposure to microbiota was achieved via low-dose dextran sodium sulfate (DSS) treatment. Rotavirus infection and replication was assessed by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse-transcription polymerase chain reaction. Diarrhea was scored visually. Humoral responses to rotavirus were measured by ELISA and enzyme-linked immunosorbent spot assay. RESULTS: Microbiota elimination delayed infection and reduced infectivity by 42%. Antibiotics did not alter ratios of positive-sense to negative-sense strands, suggesting that entry rather than replication was influenced. Antibiotics reduced the diarrhea incidence and duration, indicating that the reduction in the level of rotavirus antigen was biologically significant. Despite lowered antigen level, antibiotics resulted in a more durable rotavirus mucosal/systemic humoral response. Increased rotavirus antibody response durability correlated with increased small intestinal rotavirus-specific, immunoglobulin A-producing antibody-secreting cell concentration in antibiotic-treated mice. Conversely, DSS treatment impaired generation of rotavirus-specific antibodies. CONCLUSIONS: Microbiota ablation resulted in reduced rotavirus infection/diarrhea and a more durable rotavirus antibody response, suggesting that antibiotic administration before rotavirus vaccination could raise low seroconversion rates that correlate with the vaccine's inefficacy in developing regions.
BACKGROUND: Rotavirus causes 500 000 deaths and millions of physician visits and hospitalizations per year, with worse outcomes and reduced vaccine efficacy in developing countries. We hypothesized that the gut microbiota might modulate rotavirus infection and/or antibody response and thus potentially play a role in such regional differences. METHODS: The microbiota was ablated via germ-free or antibiotic approaches. Enhanced exposure to microbiota was achieved via low-dose dextran sodium sulfate (DSS) treatment. Rotavirus infection and replication was assessed by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse-transcription polymerase chain reaction. Diarrhea was scored visually. Humoral responses to rotavirus were measured by ELISA and enzyme-linked immunosorbent spot assay. RESULTS: Microbiota elimination delayed infection and reduced infectivity by 42%. Antibiotics did not alter ratios of positive-sense to negative-sense strands, suggesting that entry rather than replication was influenced. Antibiotics reduced the diarrhea incidence and duration, indicating that the reduction in the level of rotavirus antigen was biologically significant. Despite lowered antigen level, antibiotics resulted in a more durable rotavirus mucosal/systemic humoral response. Increased rotavirus antibody response durability correlated with increased small intestinal rotavirus-specific, immunoglobulin A-producing antibody-secreting cell concentration in antibiotic-treated mice. Conversely, DSS treatment impaired generation of rotavirus-specific antibodies. CONCLUSIONS: Microbiota ablation resulted in reduced rotavirus infection/diarrhea and a more durable rotavirus antibody response, suggesting that antibiotic administration before rotavirus vaccination could raise low seroconversion rates that correlate with the vaccine's inefficacy in developing regions.
Authors: Timo Vesikari; David O Matson; Penelope Dennehy; Pierre Van Damme; Mathuram Santosham; Zoe Rodriguez; Michael J Dallas; Joseph F Heyse; Michelle G Goveia; Steven B Black; Henry R Shinefield; Celia D C Christie; Samuli Ylitalo; Robbin F Itzler; Michele L Coia; Matthew T Onorato; Ben A Adeyi; Gary S Marshall; Leif Gothefors; Dirk Campens; Aino Karvonen; James P Watt; Katherine L O'Brien; Mark J DiNubile; H Fred Clark; John W Boslego; Paul A Offit; Penny M Heaton Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Annelie Lundin; Chek Mei Bok; Linda Aronsson; Britta Björkholm; Jan-Ake Gustafsson; Sebastian Pott; Velmurugesan Arulampalam; Martin Hibberd; Joseph Rafter; Sven Pettersson Journal: Cell Microbiol Date: 2007-12-17 Impact factor: 3.715
Authors: P J Cooper; M E Chico; G Losonsky; C Sandoval; I Espinel; R Sridhara; M Aguilar; A Guevara; R H Guderian; M M Levine; G E Griffin; T B Nutman Journal: J Infect Dis Date: 2000-09-08 Impact factor: 5.226
Authors: Mei-Lun Wang; Marcus E Shin; Pamela A Knight; David Artis; Debra G Silberg; Eunran Suh; Gary D Wu Journal: Am J Physiol Gastrointest Liver Physiol Date: 2004-12-02 Impact factor: 4.052
Authors: Andrea K Erickson; Palmy R Jesudhasan; Melinda J Mayer; Arjan Narbad; Sebastian E Winter; Julie K Pfeiffer Journal: Cell Host Microbe Date: 2017-12-28 Impact factor: 21.023
Authors: Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes Journal: Nat Rev Dis Primers Date: 2017-11-09 Impact factor: 52.329